Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Malignant Female Reproductive System Neoplasm × Heparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3 Venous Thrombosis 2 Thromboembolism 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Immunoblastic Lymphadenopathy 2 Hodgkin Disease 2 Burkitt Lymphoma 2 Wilms Tumor 1 Waldenstrom Macroglobulinemia 1 Venous Thromboembolism 1 Thrombosis 1 Testicular Neoplasms 1 Spinal Stenosis 1 Sezary Syndrome 1 Sarcoma 1 Resected Liver Metastases From Colorectal Cancer 1 Recurrence 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Osteosarcoma 1

Interventions

Specimen Handling 2 palbociclib 1 neratinib 1 Palliative Care 1 Methadone 1 Mental Status and Dementia Tests 1 Magnetic Resonance Spectroscopy 1 Interviews as Topic 1 Hydromorphone 1 Heparin 1 Enoxaparin 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356329 2016-05-13

Lovenox

National Guard Health Affairs

Phase 3 Suspended

Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡